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Abstract 
The Prevalence and Outcomes of Morphine Use in the Initial Management of Patients with 
Acute Myocardial Infarction 
 
Parker T. Landis, BSN-H 
 
University of Pittsburgh, 2018 
 
 
 
 
Background: Morphine has been historically used for the initial management of pain in patients 
with suspected acute myocardial infarction (MI). There is controversial evidence that suggests that 
morphine use is associated with adverse outcomes in both ST-elevation and non-ST-elevation MI. 
Purpose: We sought to define the prevalence and outcomes of morphine use in the initial 
management of patients with suspected acute MI in the emergency department. Theoretical 
Framework: Some studies suggest that morphine delays and attenuates the action of anticoagulants 
in patients with MI, which might lead to adverse cardiac outcomes.  Methods: This was a secondary 
analysis of Electrocardiographic Methods for the Prompt Identification of Coronary Events 
(EMPIRE) study. EMPIRE was a prospective, observational, cohort study that enrolled 
consecutive chest pain patients transported by ambulance to three UPMC-affiliated tertiary care 
hospitals. Pertinent clinical data were obtained from charts, including intravenous morphine 
administration up to procedural intervention (independent variable). The presence of the following 
clinical outcomes (dependent variables) was adjudicated by two independent reviewers: infarct 
size (defined by peak troponin level), myocardial dysfunction (defined by left ventricular ejection 
fraction), and major adverse cardiac events (MACE, defined as death, fatal ventricular arrhythmia, 
acute heart failure, pulmonary edema, cardiogenic shock, reinfarction, or repeat catheterization 
within 30 days of indexed admission). Results: Our sample included 155 patients with confirmed 
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acute MI (age 64±16, 42% females, 29% Blacks). Patients who received morphine (n=58, 37%) 
were older and had higher pain scores, but there were no other baseline differences clinical 
characteristics. In multivariate analyses, morphine use was not associated with infarct size, 
myocardial dysfunction, or MACE after controlling for MI type and other potential confounders. 
Conclusions: In this cohort, we found that morphine use in the initial management of acute MI is 
not associated with increased risk of adverse cardiac outcomes. 
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1.0 INTRODUCTION 
According to the Centers for Disease Control and Prevention, in 2010, upwards of 7 million 
people visited an emergency department (ED) with chest pain nationwide; additionally, ischemic 
heart disease accounted for about 2.3% of ED discharge diagnoses (2014). Identifying patients 
with acute cardiovascular distress is a top priority, in order to maintain viable tissue perfusion and 
minimize damage. Such life-threatening etiologies include acute myocardial infarction (AMI), 
aortic dissection, cardiac tamponade, tension pneumothorax, and pulmonary embolism. Beyond 
the immediate life-threatening causes, chest pain can be precipitated by a wide range of etiologies, 
including pericarditis, esophagitis, cardiomyopathy, heart failure, pulmonary disease, valvular 
disease, musculoskeletal pain, etc. (Weinstock et al., 2015). Accordingly, identifying the exact 
etiology of chest pain requires extensive diagnostic testing and constitutes an ongoing challenge 
in emergency practice. Too often, patients are discharged with unspecified chest pain, only 
equipped with the instructions explaining the signs and symptoms that warrant a return to the ED. 
In a meta-analysis containing studies published between 1996 and 2010, the prevalence of patients 
diagnosed with nonspecific chest pain was 44% (Ruddox, Mathisen, & Otterstad, 2012). 
Inappropriate specificity of diagnostics, poor clinical judgement, and noncompliance with 
hospital procedures results in patients being discharged prematurely or unnecessarily admitted. In 
a study of patients admitted with suspected AMI, there was a 9% rate of non-AMI diagnosis at 
discharge (Barrabés et al., 2018). An overabundance of chest pain patients admitted to a hospital 
 2 
for observation or diagnostics presents a burden on healthcare systems, consumption of resources, 
and unnecessary stress for the patient (Weinstock et al., 2015). 
Due to the vague nature of diagnosing chest pain, the treatment of nonspecific chest pain 
presentation becomes managing the symptoms rather than diagnosing the underlying cause. 
Therefore, to accurately and effectively manage and diagnose chest pain, guidelines have adapted 
based on the best evidence-based clinical practice. Guidelines are established in hospital protocols 
to assist the healthcare providers through the assessment, diagnosis, planning, intervention and 
evaluation phases of acute treatment. Protocols are imperative to efficiently and effectively 
stabilize acutely sick patients. In the emergency setting, it is a race against time. Furthermore, 
when a patient is experiencing an ischemic emergency, “time is tissue,” which is why time must 
be prioritized towards effective and beneficial interventions. Across the cardiac literature, there is 
a big focus on reducing total ischemic time (Peterson, Syndergaard, Bowler & Doxey, 2012). 
When a patient presents with chest pain to an emergency setting such as the ED, protocols 
are followed to assess and diagnose the underlying cause. A history and physical, a 12-lead 
electrocardiogram (ECG), and a chest X-ray are usually the first actions taken because they are the 
quickest and least invasive diagnostic procedures that can rule out ACS or other life-threatening 
conditions (Hollander & Chase, 2016). Further diagnostic testing may include Computed 
Tomography (CT) coronary angiography, Nuclear Stress testing, echocardiography, and 
diagnostic catheterization to determine the extent of coronary artery disease and ischemic 
myocardium (Sørgaard et al., 2017). Many of these diagnostic tests are performed during the 
inpatient stay, which may unnecessarily contribute to the burden on healthcare resources. 
An AMI is defined as acute myocardial injury with clinical evidence of acute myocardial 
ischemia and with detection of a rise and/or fall of cardiac troponin values (Thygesen et al., 2018). 
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Evidence of myocardial ischemia may be detected with an ECG. Furthermore, the presence of 
ischemic symptoms may present as diffuse or localized pain in the chest, mandible, epigastric or 
upper extremity regions. Ischemic symptoms may alternatively present as dyspnea, nausea, 
indigestion, shortness of breath, or diaphoresis (Amsterdam, et al., 2104). 
ECG changes such as ST-segment elevation, ST-segment depression, and T-wave 
inversion may be indicative of cardiac ischemia. An ST-elevation myocardial infarction (STEMI) 
is a thrombotic coronary event that results in a transmural occlusion of the coronary artery leading 
to myocardial ischemia and infarction (Montecucco, Carbone & Schindler, 2015). However, if the 
ECG is unremarkable, further testing such as serial troponin assays can be drawn to rule out a non-
STEMI (NSTEMI). In the absence of ST-elevation, NSTEMI can be diagnosed if there is 
significantly high troponin serum value, which is a unique enzyme that has a delayed release from 
infarcted myocardium. If AMI is suspected, then the patient may require emergent coronary 
catheterization with percutaneous coronary intervention (PCI) or fibrinolytic therapy to re-
cannulate the coronary artery and reperfuse the myocardium. Unfortunately, the majority of 
patients may spend several hours on a cardiac observation unit for evaluation of potential elevation 
in serum troponin, furthermore, contributing to significant consumption of hospital resources and 
unnecessary costs (Rivero, 2017).  
A history and physical, an ECG, and a serial troponin is the generic diagnostic workup for 
any patient with suspected AMI. Consequently, these diagnostic tests may take up valuable time 
which can be costly to myocardial salvage. In the circumstances of AMI, the main goal of treatment 
is to reperfuse the myocardium as soon as possible to minimize infarcted tissue and reduce major 
adverse cardiac outcomes (Montecucco et al., 2015). In order to compensate for the delayed action 
of ultimately recannulating the occluded coronary artery, institutional protocols, algorithms, and 
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decision-making models have been fabricated to direct healthcare providers in the acute treatment 
of STEMIs and NSTEMIs (Shah & Nathan, 2018). Morphine, oxygen, nitroglycerin, and aspirin 
(MONA) has been the gold standard treatment in minimizing myocardial damage and infarction 
for patients experiencing AMI in the emergency setting (Amsterdam et al., 2014; Kleinman et al., 
2018; Kristensen & Aboyans, 2018; O'Gara et al., 2013; Roffi et al., 2016).  
Priority interventions for AMI include pain management which may include morphine 
administration depending on the severity and persistence of chest pain. Given the pathophysiology 
of an AMI, pain management is a priority intervention. Chest pain develops from myocardial 
ischemia and hypoxemia because there is an imbalance between oxygen supply and oxygen 
demand in the myocardium (Thygesen et al., 2018). Pain increases sympathetic activation which 
leads to increased heart rate and blood pressure, thus increasing cardiac workload resulting in a 
greater oxygen demand and further damaging myocardium. In some studies, the duration and 
severity of chest pain has been associated with more complications (AbuRuz, 2016; Assaad et al., 
2013; Herlitz et al., 1984; Herlitz, Richter, Hjalmarson & Holmberg, 1986). In order to break that 
positive feedback loop, pain management is a top priority to prevent unnecessary additional 
damage to myocardium, especially important in the early stages of AMI.  
When AMI is indicated at any point, it is necessary to administer MONA in accordance 
with AMI guidelines. However, even with the help of guidelines, controversy over the best 
treatment is made evident by conflicting opinions introduced by emerging clinical research. 
Recently, evidence-based medicine suggests the use of morphine in AMI patients may not be the 
best treatment (Meine et al., 2005). 
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2.0 BACKGROUND 
Guidelines recommend morphine administration in AMI patients because morphine’s 
analgesic effects control pain, reduce anxiety, and decreases heart rate, blood pressure, and venous 
return (Everts, Karlson, Herlitz & Hedner, 1998). Another added benefit is that it is conveniently 
accessible and easily administered intravenously in an emergency setting. However, emerging 
literature challenges the benefits of morphine use in AMI patients (McCarthy, Bhambhani, 
Pomerantsev & Wasfy, 2017). 
When considering the latest guidelines for AMI, the most recent (2013) American College 
of Cardiology (ACC) Foundation and American Heart Association (AHA) guidelines state, “In the 
absence of a history of hypersensitivity, morphine sulfate is the drug of choice for pain relief in 
patients with ST-segment elevation MI (STEMI).” These guidelines have no formal class of 
recommendation (COR) or designated level of evidence (LOE) supported. On the other hand, in 
the updated 2017 European Society of Cardiology (ESC) STEMI guidelines gives opioids a class 
IIa COR and a LOE ‘C’ based on expert opinion. This is a drawback from a class I COR in the 
2012 ESC STEMI guidelines. The 2017 ESC STEMI guidelines comes with a disclaimer that, 
“morphine use is associated with a slower uptake, delayed onset of action, and diminished effects 
of oral antiplatelet agents.”  
The most recent ACC/AHA NSTEMI guidelines (2014) support morphine use with a class 
IIb recommendation, following a steady downgrade from class I in the 2007 guidelines revision. 
The most recent ESC NSTEMI guidelines (2015) provide no COR, however, they acknowledge 
emerging research by disclaiming “morphine may slow intestinal absorption of oral platelet 
inhibitors.” There is a strong need for research regarding morphine and its benefits. A LOE ‘C’ is 
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the weakest tier supported by research evidence. Healthcare providers are beginning to 
acknowledge research-based medicine and reconsider the effectiveness of morphine for analgesic 
effects in AMI patients. This is made evident by the subtle changes in guidelines made over that 
past decade. These changes made over the past two decades can be visualized in Table 1. 
Table 1: History of Morphine Guidelines 
 
 * Indicates most recent guidelines 
 
A pivotal part to myocardial salvage in the immediate treatment of AMI involves oral 
anticoagulation therapy, such as aspirin and P2Y12 receptor antagonists (Yusuf et al., 2001). It is 
believed that a suboptimal response to an antiplatelet regimen may be associated with adverse 
cardiovascular and cerebrovascular outcomes. Also, poor inhibition of platelet aggregation may 
lead to a higher risk of stent thrombosis in such patients (Buonamici et al., 2007; Cuisset et al., 
2006; Gurbel, Bliden, Hiatt & O’Connor, 2003; Matetzky et al., 2004). For these reasons, early 
and aggressive anticoagulation therapy is recommended and has shown to improve outcomes in 
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AMI (Alexander et al., 2008; Cohen & Downey, 2014; Parodi et al., 2013; Patti et al., 2011; 
Roubille et al., 2012). 
 Morphine raises concerns that would not support the use in AMI patients. Several common 
opioid side effects may contradict the desired therapeutic effect. Nausea, vomiting, and inhibition 
of peristalsis may negatively impact the absorption of oral medications. Anticoagulants prevent 
additional myocardial damage by inhibiting platelet accumulation in the potentially thrombus-
occluded coronary artery. In basic experimental studies, evidence suggests morphine decreases the 
absorption and delays the onset of platelet inhibition in the co-administration of morphine and oral 
anticoagulants, specifically P2Y12 receptor antagonists such as clopidogrel, ticagrelor, and 
prasugrel (Hobl et al., 2014; Hobl et al., 2016a; Hobl et al., 2016b; Parodi et al., 2015; Silvain et 
al., 2016; Thomas et al., 2016). For this reason, there is a need for research that explores the 
outcomes of AMI patients who receive morphine.  
Morphine administration is significantly associated with increased pain severity (AbuRuz, 
2016; Deng et al., 2018; Herlitz et al., 1986), however, recent studies suggest pain severity has not 
been found to increase the probability of AMI or major adverse cardiac events (MACE) (Body et 
al., 2016; Edwards et al., 2011; Galinski et al., 2015). Therefore, morphine administration may be 
unnecessarily putting AMI patients at an increased risk of adverse outcomes due to a 
prothrombotic state.  
Discussed further is how recent literature has been inconclusive regarding the benefits and 
risks related to morphine administration in AMI patients. Research is focused on studying the 
clinical implications of morphine administration such as length of hospital stay, myocardial 
infarction size, and in-hospital and 30 days MACE. For example, several articles reported 
morphine administration is associated with a larger infarct size in STEMI patients who undergo a 
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primary PCI (Bellandi et al., 2016; de Waha et al., 2015; Farag et al., 2018). Furthermore, in two 
large retrospective studies observing NSTEMI cases, morphine was associated with larger infarct 
size, longer length of stay (McCarthy et al., 2017), and increased hospital mortality (Meine et al., 
2005). On the other hand, four large scale studies published in the last three years have concluded 
that there is no excess risk with morphine administration to STEMI patients in terms of infarct size 
and 1-year MACE (Bonin et al., 2018; Gwag et al., 2017a; Gwag et al., 2017b; Puymirat et al., 
2015). There is controversy regarding the efficacy and safety of morphine administration in AMI 
patients.  
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3.0 PURPOSE AND SPECIFIC AIMS 
The purpose of this study is to evaluate the adverse effects of morphine use in AMI patients 
using a cohort of 2,065 patients who presented to a UPMC ED via EMS with a chief complaint of 
chest pain. Findings can inform the appropriateness of morphine for use in patients with AMI.  
Specific Aim 1: Determine the prevalence of morphine use among patients treated for chest 
pain pre-hospital and in-hospital: 
Aim 1(a). What is the prevalence of morphine administration among AMI patients? 
STEMI? NSTEMI? 
Aim 1(b). Are there demographical and clinical differences between patients who did and 
did not receive morphine? 
Specific Aim 2: Evaluate the relationship between morphine administration and clinical 
outcomes in patients with STEMI vs. NSTEMI: 
Aim 2(a). Is there a relationship between morphine use and size of infarct in STEMI vs. 
NSTEMI patients after controlling for potential confounders? 
Aim 2(b). Is there a relationship between morphine use and myocardial dysfunction in 
STEMI vs. NSTEMI patients after controlling for potential confounders? 
Aim 2(c). Is there a relationship between morphine use and 30-day MACE in STEMI vs. 
NSTEMI patients after controlling for potential confounders? 
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4.0 METHODS 
4.1 DESIGN AND SETTING 
This was a secondary analysis of Electrocardiographic Methods for the Prompt 
Identification of Coronary Events (EMPIRE) study (Al-Zaiti, Martin-Gill, Sejdić, Alrawashdeh, 
& Callaway, 2015). EMPIRE is a prospective, observational, cohort study that enrolled 
consecutive chest pain patients transported by ambulance to three University of Pittsburgh Medical 
Center (UPMC)-affiliated tertiary care hospitals, UPMC Mercy, UPMC Shadyside, and UPMC 
Presbyterian. EMPIRE is an ongoing study that recruits patients into three phases: cohort 1 (2013–
2014, n=2,065), cohort 2 (2014–2016, n=3,350), and cohort 3 (2016–2017, n=1,785). This 
secondary analysis includes patients in cohort 1 because the clinical outcomes adjudication for 
cohorts 2 and 3 is still ongoing.  
The EMPIRE study was approved by the Institutional Review Board (IRB) of University 
of Pittsburgh. This study is minimal risk as it collected routine care data and there is no patient 
contact; data were extracted from electronic medical records by reviewers blinded to study 
outcomes. All extracted data were de-identified before storage and a linkage list was kept separate 
from the data; both measures were taken to reduce the risk of breach of confidentiality. The current 
secondary analysis was approved by Dr. Salah Al-Zaiti. 
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4.2 STUDY POPULATION AND SIZE 
The cohort included 2,065 chest pain patients transported to the ED by ambulance. A total 
of 155 patients with confirmed AMI were included in the study. The presence of AMI was 
adjudicated by two independent reviewers after review of course of hospitalization. MI type 
(STEMI vs. NSTEMI) was retrieved from cardiac catheterization report as determined by the 
interventional cardiologist at time of patient care. Figure 1 demonstrates the patient flow diagram.  
 
Figure 1: Distribution of Sample 
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4.3 VARIABLES AND DATA COLLECTION 
The morphine group included patients who received intravenous (IV) morphine during 
prehospital transport or during in-hospital stay prior to catheterization. This includes 
administration up to the point of percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG). Patients with a medically managed MI who received IV morphine were 
included in the morphine group. If morphine was administered post-procedural, the patient was 
included in “no morphine administration” group. 
Each patient chart was systematically reviewed by a single primary reviewer. Age, sex, 
race, body mass index (BMI), and smoking history demographics were retrieved in all the charts. 
The independent variable included pre-procedural IV morphine administration. Dependent 
variables included past medical history (PMH), culprit lesions defined by a coronary vessel 70% 
occluded, and presenting signs and symptoms. Presenting signs and symptoms retrieved included 
prehospital heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure, pain 
severity prior to morphine administration, shortness of breath, gastrointestinal (GI) upset, and 
diaphoresis. Initial blood creatinine value and blood glucose value were retrieved with the first 
blood labs prior to intervention. Additional data included admission time/date, length of stay, 
morphine dose and time of first morphine administration, time of first three consecutive troponin 
blood values, and pre-procedural aspirin and nitroglycerin administration, and oxygen 
administration at the ED. 
Two independent reviewers adjudicated the following primary clinical outcomes: infarct 
size, myocardial dysfunction, and 30-day major adverse cardiac events (MACE). Infarct size was 
defined by the peak serum troponin level during entire length of hospitalization. A higher spike in 
serum troponin is associated with increased myocardial infarction (Mohammad et al., 2018). 
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Myocardial dysfunction was defined by left ventricular ejection fraction (LVEF). LVEF was 
obtained from the post-procedural echocardiogram. A reduced LVEF post-MI is indicative of 
decreased myocardial function and efficiency due to presumed ischemic damaged or infarct 
myocardium. This is associated with increased incidence of heart failure with worse long-term 
outcomes (Ndrepepa., 2018). The 30-day MACE was defined as all cause death, fatal ventricular 
arrhythmia, acute heart failure, pulmonary edema, cardiogenic shock, re-infarction, or repeat 
catheterization within 30 days of indexed admission. Primary clinical outcomes and elements of 
MACE were defined in congruence with ACC/AHA Key Data Elements and Definitions for 
Cardiovascular Endpoint Events in Clinical Trials (2015). Patient charts were followed for 30 days 
after discharge and clinical data was included in the cases of repeat ED or in-hospital admission.  
4.4 STATISTICAL ANALYSIS 
Level of significance was set at p<0.05 for two-sided hypothesis testing. SPSS Statistics 
software version 24 of International Business Machines (IBM) Corporation in Armonk, New York, 
was utilized to process the data. Continuous variables were reported as means ± SD or median 
[25th – 75th percentiles], categorical variables were reported as n (%). Groups (morphine 
administration vs. no morphine administration) were compared using t-test for continuous 
variables and chi-square for categorical variables. Univariate and multivariate models were 
constructed for each outcome variable. Simple linear regression was used for peak troponin level 
(surrogate for infarct size) and LVEF (surrogate for myocardial dysfunction). Logistic regression 
was used for 30-day MACE. Variables significant at p<0.10 in univariate analysis were entered in 
backward selection method in multivariate analysis. All models were computed separately for 
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patients with STEMI vs. NSTEMI. Log transformation was used for variables that were not 
normally distributed, namely peak troponin level that was severely positively skewed. 
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5.0 RESULTS 
5.1 SPECIFIC AIM 1 
Specific Aim 1 sought to define the prevalence of morphine administration among AMI 
patients and evaluate differences in baseline characteristics between those who did and did not 
receive morphine. Of 2,065 chest pain patients, our study sample included 155 patients with 
confirmed acute MI (age 64±16, 42% females, 29% Blacks). Among those with acute MI, a total 
of 97 patients (63%) did not receive IV morphine and 58 patients (37%) received IV morphine. 
The distribution of AMI patients was observed as 73(47%) NSTEMI and 82(53%) STEMI. Of 
these, 34/82 (41%) STEMI patients were administered IV morphine, compared to 24/73 (33%) 
NSTEMI patients who received IV morphine.  
 
Figure 2: Distribution of morphine administration 
Table 1 compares the baseline variables between these two groups. When comparing 
demographics between the two groups, there were no difference seen in sex, BMI, race, or 
smoking. There were no variables in PMH or vessel occlusions that were statistically different 
among the two groups. Patients who received morphine were younger (61±18, p=0.03), presented 
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with a lower serum glucose (147±51, p=0.019) and reported a higher pain score (7.4±2.6, 
p=<0.001); no other differences in baseline clinical characteristics were observed. The distribution 
of treatment was seen as 4/58 (7%) were treated with CABG, 13/58 (22%) were treated with 
medical management, and 41/58 (71%) were treated with PCI.  
 
Figure 3: Significant differences among morphine and no morphine administration groups 
5.2 SPECIFIC AIM 2 
Specific Aim 2 evaluated the relationship between morphine administration and clinical 
outcomes in STEMI and NSTEMI patients by running two separate models for univariate and 
multivariate analyses. In the STEMI regression model, there were no univariate or multivariate 
statistically significant predictors of infarct size. Hypertension (HTN) (p=0.037), respiratory rate 
(RR) (p=0.048), and oxygen administered at the ED (p=0.002) were independent predictors of 
infarct size in NSTEMI patients. However, morphine did not predict infarct size in either STEMI 
or NSTEMI patients (Table 2). 
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The second regression model observed variables that predicted myocardial dysfunction in 
the STEMI and NSTEMI groups. Sex (p=0.044), known heart failure (p=0.014), and left anterior 
descending (LAD) occlusion (p=0.002) were independent predictors of myocardial dysfunction in 
STEMI patients. Shortness of breath (p=0.049) was the only independent predictor of myocardial 
dysfunction in NSTEMI patients. Morphine was not statistically significant to predict myocardial 
dysfunction in either STEMI or NSTEMI patients (Table 3), however morphine was significant in 
the univariate model for the NSTEMI group. 
A third regression model evaluated predictors of 30-day MACE. Systolic blood pressure 
(p=0.041) and creatinine (p=0.017) predicted 30-day MACE in STEMI patients. Prior CABG 
(p=0.040) and glucose (0.029) predicted 30-day MACE in NSTEMI patients. There were no other 
PMH or presenting signs or symptoms that predicted 30-day MACE in either group. Morphine did 
not predict 30-day MACE in either MI group (Table 4). 
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6.0 DISCUSSION 
The purpose of this study was to evaluate the association of morphine with clinical 
outcomes in the setting of AMI. Our results have shown that approximately 58(37%) of AMI 
patients receive IV morphine (34[41%] of STEMI and 24[33%] of NSTEMI). After controlling 
for MI type and other potential confounders in a multivariate regression model, morphine 
administration was not associated with infarct size, myocardial dysfunction, or 30-day MACE. 
Study findings suggest that morphine administration does not lead to excess risk in patients with 
acute MI. 
6.1 PREVALENCE OF MORPHINE ADMINISTRATION 
In this study, younger patients and those with higher reported pain score were more likely 
to be administered IV morphine. Pain has proven to be a major indicator of morphine 
administration (AbuRuz, 2016; Deng et al., 2018; Herlitz et al., 1986), as well as a younger age 
(Bonin et al., 2018; de Waha et al., 2015; Gwag et al., 2017b; McCarthy et al., 2017; Puymirat et 
al., 2015) in several studies involving nonrandomized morphine administration. Morphine is 
indicated for severe chest pain unrelieved by nitroglycerin. Therefore, this is an expected outcome 
in our data. We found younger patients report more severe pain when experiencing acute chest 
pain, therefore are administered morphine more frequently. This can be due to the fact that severe 
illness is more common in older adults, therefore more attention may be given to diagnostic work 
instead of pain relief (Platts-Mills et al., 2012).  
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In addition, we found that those with lower serum glucose level were more likely to be 
administered morphine. It remains unknown if this is due to altered pain level perception due to 
poor blood glucose or diabetic control, given that those who presented with a significantly higher 
blood glucose were not significantly associated with morphine administration. 
6.2 SAFETY OF MORPHINE ADMINISTRATION 
There is strong evidence that dual antiplatelet therapy (DAPT) has proven to be a pivotal 
intervention in AMI outcomes. This includes an early loading dose of a P2Y12 inhibitor prior to 
PCI (Dörler et al., 2011). However, morphine combined with oral P2Y12 inhibitors poses an 
adverse effect that delays the anticoagulation action in AMI patients (Silvain et al., 2016). For this 
reason, co-administration of morphine and oral P2Y12 inhibitors raises concerns regarding the 
safety of morphine use in AMI patients. A recent study utilized myocardial salvage index (MSI) 
to determine whether IV morphine affects myocardial injury in STEMI patients who received 
DAPT prior to PCI. They determined IV morphine was not associated with adverse outcomes in 
myocardial salvage (Gwag et al., 2017b). Our results are consistent with these findings and support 
that morphine administration is unlikely to lead to profound adverse events in AMI.  
6.3 CLINICAL IMPLICATIONS 
Several recent studies determining the adverse effects of morphine in STEMI patients do 
not draw definitive conclusions regarding clinical outcomes. Instead, they provide evidence 
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concerning surrogate values that serve as prognostic markers of reperfusion success in STEMI 
patients. Some surrogate values used by these studies to define AMI prognosis are peak troponin, 
MSI, TIMI-flow, LVEF, and platelet reactivity index (de Waha et al., 2015; Gwag et al., 2017b). 
Without a longer follow-up duration, conclusions cannot be drawn about the clinical outcomes of 
IV morphine use in STEMI patients, while only using surrogate values. Evidence from this study 
shows that IV morphine use in STEMI patients is not associated with 30-day MACE after 
controlling for confounding variables in a multivariate regression model. This is consistent with 
the outcomes of one large, nonrandomized, retrospective study of 2,438 STEMI patients who 
received IV morphine prior to PCI concluding 1-year MACE was not associated with IV morphine 
(Puymirat et al., 2015). Given the latest published evidence there is no indication that morphine 
should be contraindicated in STEMI patients. This is based on clinical outcomes of studies that 
report no association of morphine and MACE, mortality, or length of hospital stay (LOS) (Bellandi 
et al., 2016; Bonin et al., 2017; de Waha et al., 2015; Farag et al., 2018; Puymirat et al., 2016) .  
Contrary to our findings, Meine, T.J. et al. (2004) evaluated the association of IV morphine 
use and ACS outcomes in a sample of 17,003 NSTEMI patients and found IV morphine was 
significantly associated with higher mortality in NSTEMI patients after propensity score matched 
analysis. Likewise, in a 2017 study of 1740 NSTEMI patients, IV morphine was statistically 
significant for a larger infarct size and longer LOS after propensity score matching (McCarthy et 
al., 2017). Although morphine was not a significant predictor of infarct size or myocardial 
dysfunction in our study, it was borderline significant in both outcomes. With a larger sample size 
this may become significant. Given the controversial evidence, it is unclear whether the risk of 
morphine administration may exceed the benefits in NSTEMI patients. Further research including 
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randomized controlled trials that observe clinical outcomes is warranted before a clear conclusion 
or recommendation can be drawn.  
6.4 LIMITATIONS 
There were several limitations observed in our study. This study lacks power due to the 
small sample size and a nonrandomized model. With a larger sample size, other confounding 
variables can be controlled for which may lead to significant statistical results. Morphine dosage 
and timing was collected, however could not be included do to a large skew in data. Do to the 
chaotic and rushed environment in the ED, verbal order medications and a thorough history and 
physical were undocumented or underreported. Several patients received acute care in a UPMC 
affiliated ED while visiting Pittsburgh from other states. Their charts were unable to be accessed 
for the 30-day follow up data because the follow up data were inaccessible from another hospital 
system. Patients from this study were enrolled from 2012 to 2013, thus temporal changes in 
practice at UPMC emergency medicine may have occurred by the time these data were analyzed.  
6.5 CONCLUSION 
In this study, morphine use was not associated with infarct size, myocardial dysfunction, 
or MACE after controlling for MI type and other potential confounders. Pending undisputed 
evidence from randomized controlled trials, current guidelines should continue to be followed for 
the management of AMI patients. As more attention is drawn to this topic, there will be increasing 
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literature published. Future updates to recommended ACC/AHA AMI guidelines can be expected 
considering the recent trend of guideline publications over the past decade. It would behoove the 
nurses and other providers in the ED setting to be educated on this matter, in order to implement 
the best patient centered care and evidence-based practice.  
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Appendix A Results 
Demographic and clinical characteristics of the study sample are found in Table 2. The 
regression models evaluating the predictors of each major clinical outcome in STEMI vs. NSTEMI 
are presented in Table 3 (infarct size), Table 4 (myocardial dysfunction), and Table 5 (30-day 
MACE). 
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Table 2: Demographic and Clinical Characteristics 
 
 
 
Demographics 
Morphine Administration 
(n=58) 
No Morphine 
Administration (n=97) 
P-Value 
Age (years)±SD 61±18 66±14 0.030 
BMI (kg/m2)±SD 31.2±8.5 29.6±6.8 0.190 
Male 60% 58% 0.730 
Black 36% 25% 0.148 
Smoker 67% 57% 0.461 
Medical History 
HTN 74% 70% 0.587 
DM2 35% 31% 0.724 
HLD 50% 54% 0.622 
HF 19% 12% 0.237 
CAD 45% 38% 0.400 
Angina 19% 9.40% 0.136 
Prior MI 28% 28% 0.940 
PAD 9% 6% 0.748 
Prior Stroke 8.50% 10.40% 0.339 
Chronic Lung Disease 28% 21% 0.432 
Prior PCI 29% 25% 0.577 
Prior CABG 14% 14% 0.965 
Vessel Occlusion 
LAD (%)±SD 81±21 75±27 0.269 
LCx (%)±SD 68±28 66±27 0.743 
RCA (%)±SD 75±30 76±30 0.905 
Culprit Lesion 
LAD 41% 49% 0.406 
LCx 19% 23% 0.686 
RCA 36% 36% 0.975 
Presenting Signs 
Cr median(25th-75th percentile) 1.0[0.8-1.2] 1.0[0.9-1.3] 0.175 
Glucose (mg/dL)±SD 147±51 175±95 0.019 
SOB 59% 52% 0.505 
Diaphoresis  40% 46% 0.504 
GI Upset  43% 47% 0.496 
PH HR (beat/min)±SD 86±20 84±31 0.730 
PH RR (Respirations/min)±SD 20±4 19±4 0.180 
PH SaO2 (%)±SD 98±3 98±3 0.510 
PH SBP (mmHg)±SD 144±36 146±43 0.830 
PH DBP (mmHg)±SD 86±27 86±22 0.900 
Pain (0-10)±SD 7.4±2.6 3.9±3.5 <0.001 
Outcomes 
STEMI 58% 51% 0.503 
LOS 3.0[2.3-5.2] 3.2[2.2-4.9] 0.581 
Peak Troponin level 13.8(3.6-77.4) 7.9(1.3-29.2) 0.283 
LVEF (%)±SD 50±13 52±11 0.465 
30day MACE 28% 33% 0.290 
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Table 3: Univariate and Multivariate Predictors of Infarct Size 
 
Predictors 
STEMI (82) NSTEMI (73) 
Univariate Multivariate  Univariate Multivariate 
Demographics 
Age 
Sex 
Race 
BMI 
Smoking 
 
Past Medical History 
HTN 
DM 
Dyslipidemia 
Known HF 
CAD 
Angina 
Prior MI 
PAD 
Prior Stroke 
Chronic Lung Disease 
Prior PCI 
Prior CABG 
 
Clinical Presentation 
SOB 
Diaphoresis 
GI Upset 
HR 
RR 
SBP 
DBP 
O2 Sat 
Pain Score 
 
Diagnostic Workup 
Glucose 
Creatinine 
LAD Occlusion 
LCX Occlusion 
RCA Occlusion 
 
Initial Treatment 
Oxygen at the ED  
IV Morphine 
 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
 
 
– 
– 
 
 
NS 
NS 
NS 
NS 
NS 
 
 
p = 0.080 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
p = 0.049 
p = 0.034 
NS 
NS 
NS 
0.073 
 
 
NS 
NS 
NS 
NS 
NS 
 
 
p = 0.002 
p = 0.086 
 
 
– 
– 
– 
– 
– 
 
 
p = 0.037 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
p = 0.073 
p = 0.048 
– 
– 
– 
p = 0.284 
 
 
– 
– 
– 
– 
– 
  
 
p = 0.002 
p = 0.133 
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Table 4: Univariate and Multivariate Predictors of Myocardial Dysfunction 
 
Predictors 
STEMI (82) NSTEMI (73) 
Univariate Multivariate  Univariate Multivariate 
Demographics 
Age 
Sex 
Race 
BMI 
Smoking 
 
Past Medical History 
HTN 
DM 
Dyslipidemia 
Known HF 
CAD 
Angina 
Prior MI 
PAD 
Prior Stroke 
Chronic Lung Disease 
Prior PCI 
Prior CABG 
 
Clinical Presentation 
SOB 
Diaphoresis 
GI Upset 
HR 
RR 
SBP 
DBP 
O2 Sat 
Pain Score 
 
Diagnostic Workup 
Glucose 
Creatinine 
LAD Occlusion 
LCX Occlusion 
RCA Occlusion 
Initial Treatment 
Oxygen at the ED  
IV Morphine 
 
 
NS 
p = 0.016 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
p = 0.013 
NS 
NS 
NS 
p = 0.071 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
p = 0.001 
NS 
NS 
 
NS 
NS 
 
– 
p = 0.044 
– 
– 
– 
 
 
– 
– 
– 
p = 0.014 
– 
– 
– 
p = 0.393 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
p = 0.002 
– 
– 
 
– 
– 
 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
p = 0.060 
p = 0.052 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
p = 0.023 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
 
NS 
p = 0.046 
 
– 
– 
– 
– 
– 
 
 
– 
– 
p = 0.084 
p = 0.361 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
p = 0.049 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
 
– 
p = 0.084 
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Table 5: Univariate and Multivariate Predictors of 30-Day MACE 
 
Predictors 
STEMI (n=82) NSTEMI (n=73) 
Univariate Multivariate  Univariate Multivariate 
Demographics 
Age 
Sex 
Race 
BMI 
Smoking 
 
Past Medical History 
HTN 
DM 
Dyslipidemia 
Known HF 
CAD 
Angina 
Prior MI 
PAD 
Prior Stroke 
Chronic Lung Disease 
Prior PCI 
Prior CABG 
 
Clinical Presentation 
SOB 
Diaphoresis 
GI Upset 
HR 
RR 
SBP 
DBP 
O2 Sat 
Pain Score 
 
Diagnostic Workup 
Glucose 
Creatinine 
LAD Occlusion 
LCX Occlusion 
RCA Occlusion 
 
Initial Treatment 
Oxygen at the ED  
IV Morphine 
 
 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
p = 0.034 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
p = 0.007 
NS 
NS 
NS 
 
 
p = 0.016 
p = 0.011 
NS 
NS 
NS 
 
 
NS 
NS 
 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
p = 0.254 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
p = 0.041 
– 
– 
– 
 
 
p = 0.143 
p = 0.017 
– 
– 
– 
 
 
– 
– 
 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
p = 0.075 
 
 
p = 0.112 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
p = 0.051 
NS 
NS 
NS 
NS 
 
 
NS 
NS 
 
– 
– 
– 
– 
– 
 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
p = 0.040 
 
 
p = 0.125 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
p = 0.029 
– 
– 
– 
– 
 
 
– 
– 
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